Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

  • This share is currently suspended. It was suspended at a price of 1.2699
  • There is currently no data for ONC

PDMR Dealing

25 Mar 2020 12:42

RNS Number : 5784H
Oncimmune Holdings PLC
25 March 2020
 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

PDMR Dealing

 

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has been notified that Meinhard Schmidt, PDMR and Non-Executive Chairman, has purchased 18,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") for 49 pence per share on 24 March 2020.

 

Following this transaction, Meinhard has a total interest in the Company of 18,000 Ordinary Shares, representing approximately 0.03 per cent of the Company's issued Ordinary Share capital.  

 

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Meinhard Schmidt

2

 

Reason for the notification

a)

 

Position/status

 

Non-Executive Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

 

 

Identification code

ISIN: GB00BYQ94H38

 

 

b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price

Volume

 

 

 

£0.49

18,000

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

Same as above

 

 

- Price

 

 

 

e)

 

Date of the transaction

 

24 March 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

For further information:

Oncimmune Holdings plc

Andrew Stewart, General Counsel and Company Secretary

contact@oncimmune.com  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHKKPBQBBKDDNB
Date   Source Headline
2nd Feb 20247:00 amRNSNotice of AGM
11th Dec 20233:12 pmRNSDirector/PDMR Shareholding
8th Dec 20232:31 pmRNSGrant of Options and PDMR Dealing
30th Nov 20237:00 amRNSProgress against Strategy
10th Nov 202310:14 amRNSHolding(s) in Company
7th Nov 20234:11 pmRNSGrant of Options and PDMR Dealing
19th Oct 20237:00 amRNSInvestor Presentation via Investor Meet Company
12th Oct 20237:00 amRNSUpdate on Strategy & Changes to the Board
1st Aug 20237:00 amRNSBoard Changes
14th Jul 20232:00 pmRNSCorrected unaudited interim results to 31 May 2022
12th Jul 20237:00 amRNSAppointment of new leadership team & board changes
26th Jun 202311:10 amRNSChange of registered office
23rd Jun 20237:00 amRNSTransition of Executive Leadership
15th Jun 20235:16 pmRNSCorrection to interim results
13th Jun 20237:45 amRNSHolding(s) in Company
5th Jun 20234:02 pmRNSDirector/PDMR Shareholding
31st May 20237:00 amRNSInterim Results
22nd May 20237:00 amRNSSale of Oncimmune Limited to Freenome
3rd Apr 20234:38 pmRNSHolding(s) in Company
27th Mar 202311:07 amRNSResult of GM
3rd Mar 20237:00 amRNSPosting of Annual Report and Notice of GM
27th Feb 20232:36 pmRNSResult of AGM
27th Feb 20237:00 amRNSFinal Results
23rd Feb 20237:00 amRNSAppointment of Joint Broker
17th Feb 20237:00 amRNSSiemens Healthineers Collaboration
3rd Feb 202311:50 amRNSNotice of AGM
31st Jan 20237:00 amRNSNotice of Results
13th Jan 20237:00 amRNSAppointment of Non-Executive Director
20th Dec 20227:00 amRNSImmunoINSIGHTS Trading Update
19th Dec 20221:35 pmRNSDirector/PDMR Shareholding
14th Dec 20222:00 pmRNSResult of Capital Raising
9th Dec 20221:30 pmRNSExtension of Capital Raising
7th Dec 20222:00 pmRNSProposed Placing and Subscription
4th Nov 20224:16 pmRNSGrant of Options and PDMR Dealing
21st Sep 20222:16 pmRNSPDMR Dealing
21st Sep 20227:00 amRNSUnaudited results for the 12 months to 31 May 2022
30th Aug 20223:53 pmRNSRevised Notice of Results
15th Aug 20222:06 pmRNSHolding(s) in Company
8th Aug 202211:55 amRNSHolding(s) in Company
15th Jul 202210:44 amRNSHolding(s) in Company
13th Jul 20227:00 amRNSGrant of Options and PDMR Dealing
8th Jul 20227:00 amRNSBoard Changes and Trading Update
20th Jun 20222:19 pmRNSHolding(s) in Company
16th Jun 20229:59 amRNSHolding(s) in Company
7th Jun 202210:20 amRNSHolding(s) in Company
6th Jun 20229:30 amRNSHolding(s) in Company
1st Jun 20228:18 amRNSHolding(s) in Company
31st May 202212:41 pmRNSHolding(s) in Company
26th May 20229:57 amRNSHolding(s) in Company
23rd May 20224:27 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.